Healthcare Analyst

Wilfred Yuen

Thematic (Sector/Industry)

<ul>
<li>
Sino Biopharm licensed out ex-China rights of PDE3/4 inhibitor for upfront US$200m and obtained the China sales rights for two respiratory products of GSK. See our call takeaways for details
</li>
<li>
China expands National Essential Drug List after 8 years. Per Locust Walk 2Q26 report, China accounted for 60% of licensing deal value and 15% of  biotech VC in 1H26 globally</li>
<li>Other key news include Insilico Medicine (profit alert; rentosertib entering phase 3), Hansoh (B7H3 ADC met primary endpoint), Hengrui (oral GLP-1 positive topline data; FDA declined to approved camrelizumab/rivoceranib)...</li>
</ul>



Sino Biopharm licensed out ex-China rights of PDE3/4 inhibitor for upfront US$200m and obtained the China sales rights for two respiratory products of GSK. See our call takeaways for details


China expands National Essential Drug List after 8 years. Per Locust Walk 2Q26 report, China accounted for 60% of licensing deal value and 15% of  biotech VC in 1H26 globally
Other key news include Insilico Medicine (profit alert; rentosertib entering phase 3), Hansoh (B7H3 ADC met primary endpoint), Hengrui (oral GLP-1 positive topline data; FDA declined to approved camrelizumab/rivoceranib)...


Global Healthcare Analyst

Tina Banerjee

<ul>
<li>CSPC Pharmaceutical entered drug discovery collaboration with AstraZeneca in a deal worth of $1.7B+. Abbisko Cayman is collaborating with AstraZeneca to jointly develop a novel IO-TKI combination therapy for NSCLC.</li>
<li>Insilico inked AI drug discovery deal with Takeda Pharmaceutical worth up to $600M. Nippon Shinyaku secured exclusive worldwide rights to develop and commercialize EXG-7001 for DMD from Elixirgen Therapeutics.</li>
<li>Otsuka’s Voyxact demonstrated significant stabilization of kidney function, with evidence of improvement over two years in Phase 3 trial. EMA recommended to pull CSL’s Tavneos from sale in the EU.</li>
</ul>


CSPC Pharmaceutical entered drug discovery collaboration with AstraZeneca in a deal worth of $1.7B+. Abbisko Cayman is collaborating with AstraZeneca to jointly develop a novel IO-TKI combination therapy for NSCLC.
Insilico inked AI drug discovery deal with Takeda Pharmaceutical worth up to $600M. Nippon Shinyaku secured exclusive worldwide rights to develop and commercialize EXG-7001 for DMD from Elixirgen Therapeutics.
Otsuka’s Voyxact demonstrated significant stabilization of kidney function, with evidence of improvement over two years in Phase 3 trial. EMA recommended to pull CSL’s Tavneos from sale in the EU.


APAC Healthcare Weekly (July 5) – CSPC, Abbisko, Insilico, Takeda, Nippon Shinyaku, Otsuka, CSL

<ul>
<li>This week we saw 3 licensing deals from China biopharma: 1) CSPC/AstraZeneca on siRNA drug discovery, 2) Insilico Medicine/Takeda on AI drug discovery, 3) Metis TechBio/Deerfield’s Boulevard Bio on a trispecific TCE</li>
<li>
Innovent expands its China commercial portfolio by adding Lilly’s CDK4/6 inhibitor Verzenios; Fosun licenses China right of Junshi’s near-approval IL-17A drug for psoriasis</li>
<li>US House Committee to launch national security investigations into 5 big pharmas for clinical trials at Chinese military sites; Other companies update include Hutchmed, Abbisko, BeOne, Hengrui </li>
</ul>


This week we saw 3 licensing deals from China biopharma: 1) CSPC/AstraZeneca on siRNA drug discovery, 2) Insilico Medicine/Takeda on AI drug discovery, 3) Metis TechBio/Deerfield’s Boulevard Bio on a trispecific TCE

Innovent expands its China commercial portfolio by adding Lilly’s CDK4/6 inhibitor Verzenios; Fosun licenses China right of Junshi’s near-approval IL-17A drug for psoriasis
US House Committee to launch national security investigations into 5 big pharmas for clinical trials at Chinese military sites; Other companies update include Hutchmed, Abbisko, BeOne, Hengrui 


China Healthcare Weekly Wrap (29 Jun - 3 July)

<ul>
<li>InSilico Medicine and SK Biopharmaceuticals entered R&amp;D collaboration to discover AI-enabled neuroimmune drug candidates. Abbisko Cayman entered into a strategic research collaboration and license agreement with Eli Lilly.</li>
<li>Nippon Shinyaku’s partner Regenxbio cleared path to resubmit Hunter syndrome gene therapy candidate RGX-121 to the FDA. Otsuka announced positive topline results in Phase 3b study evaluating centanafadine in ADHD.</li>
<li>Yuhan Corp received orphan drug designation from the EMA for its Gaucher disease therapy candidate YH35995. Medytox obtained approval for its hyaluronic acid filler Neuramis Deep Lidocaine in China.</li>
</ul>


InSilico Medicine and SK Biopharmaceuticals entered R&amp;D collaboration to discover AI-enabled neuroimmune drug candidates. Abbisko Cayman entered into a strategic research collaboration and license agreement with Eli Lilly.
Nippon Shinyaku’s partner Regenxbio cleared path to resubmit Hunter syndrome gene therapy candidate RGX-121 to the FDA. Otsuka announced positive topline results in Phase 3b study evaluating centanafadine in ADHD.
Yuhan Corp received orphan drug designation from the EMA for its Gaucher disease therapy candidate YH35995. Medytox obtained approval for its hyaluronic acid filler Neuramis Deep Lidocaine in China.


APAC Healthcare Weekly (June 28) – Insilico, Abbisko, Nippon Shinyaku, Otsuka, Yuhan Corp, Medytox

<ul>
<li>We counted 5 license-out/collaboration deals this week: Antengene/K2 on TCE; Insilico/SK Bio on AI-enabled CNS drugs; Abbisko/Lilly on multiple targets; Haisco/Nuvectis on oncology/complement therapies; TrueLab/NewCo on two TL1A-targeting assets.</li>
<li>China approved 4 globally first-in-class therapies on 22 June: Biokin’s EGFR/HER3 ADC for nasopharyngeal carcinoma, CARsgen’s CLDN18.2 CAR-T for gastric cancer, CMS/Genrix’s silevimig for rabies, SBP/ProteLight’s peceleganan for wound infections.</li>
<li>Other news and updates include Hengrui, Ollin/Innovent, Sino Biopharm, Leads Biolabs, Everest, Ascletis.</li>
</ul>


We counted 5 license-out/collaboration deals this week: Antengene/K2 on TCE; Insilico/SK Bio on AI-enabled CNS drugs; Abbisko/Lilly on multiple targets; Haisco/Nuvectis on oncology/complement therapies; TrueLab/NewCo on two TL1A-targeting assets.
China approved 4 globally first-in-class therapies on 22 June: Biokin’s EGFR/HER3 ADC for nasopharyngeal carcinoma, CARsgen’s CLDN18.2 CAR-T for gastric cancer, CMS/Genrix’s silevimig for rabies, SBP/ProteLight’s peceleganan for wound infections.
Other news and updates include Hengrui, Ollin/Innovent, Sino Biopharm, Leads Biolabs, Everest, Ascletis.


China Healthcare Weekly Wrap (22-26 June)

Hong Kong

Insilico Medicine is an artificial intelligence (AI)-based biotechnology company that applies AI solutions to drug discovery and development, leveraging its proprietary Pharma.AI platform to identify and design early-stage drug candidates. The company develops novel drugs for various diseases, including cancer, fibrosis, immunity, and central nervous system disorders, and predicts clinical trial outcomes. Insilico Medicine was founded in 2014 and is headquartered in New Territories, Hong Kong.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Insilico Medicine (3696 HK)

China Healthcare Weekly Wrap (6-10 July)

Key news: 1) SBP deals with AZ and GSK, 2) China expands Essential Drug List, 3) clinical/regulatory updates from Hengrui (oral GLP-1; FDA on PD-1...

Wilfred Yuen

APAC Healthcare Weekly (July 5) – CSPC, Abbisko, Insilico, Takeda, Nippon Shinyaku, Otsuka, CSL

CSPC, Insilico, and Abiisko inked outlicensing deals with international companies. Nippon Shinyaku inlicenses DMD drug candidate. EMA recommends to...

Tina Banerjee

China Healthcare Weekly Wrap (29 Jun - 3 July)

Licensing deals continue this week: CSPC/AstraZeneca on siRNA, Insilico/Takeda on AI drugs, Metis/Deerfield's Boulevard on trispecific TCE;...

Wilfred Yuen

APAC Healthcare Weekly (June 28) – Insilico, Abbisko, Nippon Shinyaku, Otsuka, Yuhan Corp, Medytox

Few Chinese companies signed outlicensing deals. Nippon Shinyaku’s partner Regenxbio will resubmit gene therapy drug candidate to FDA. Otsuka...

Tina Banerjee

China Healthcare Weekly Wrap (22-26 June)

This week saw 5 license-out/collaboration deals in the biopharma industry and China approving 4 globally first-in-class therapies, with updates...

Wilfred Yuen

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

China Healthcare Weekly Wrap (6-10 July)

Key news: 1) ​SBP deals with AZ and GSK, 2) China expands Essential Drug List, 3) clinical/regulatory updates from Hengrui (oral GLP-1; FDA on PD-1...

Wilfred Yuen

APAC Healthcare Weekly (July 5) – CSPC, Abbisko, Insilico, Takeda, Nippon Shinyaku, Otsuka, CSL

CSPC, Insilico, and Abiisko inked outlicensing deals with international companies. Nippon Shinyaku inlicenses DMD drug candidate. EMA recommends to...

Tina Banerjee

China Healthcare Weekly Wrap (29 Jun - 3 July)

Licensing deals continue this week: CSPC/AstraZeneca on siRNA, Insilico/Takeda on AI drugs, Metis/Deerfield's Boulevard on trispecific TCE;...

Wilfred Yuen

APAC Healthcare Weekly (June 28) – Insilico, Abbisko, Nippon Shinyaku, Otsuka, Yuhan Corp, Medytox

Few Chinese companies signed outlicensing deals. Nippon Shinyaku’s partner Regenxbio will resubmit gene therapy drug candidate to FDA. Otsuka...

Tina Banerjee

China Healthcare Weekly Wrap (22-26 June)

​This week saw 5 license-out/collaboration deals in the biopharma industry and China approving 4 globally first-in-class therapies, with updates...

Wilfred Yuen

Key news: 1) SBP deals with AZ and GSK, 2) China expands Essential Drug List, 3) clinical/regulatory updates from Hengrui (oral GLP-1; FDA on PD-1...

This week saw 5 license-out/collaboration deals in the biopharma industry and China approving 4 globally first-in-class therapies, with updates...